Pronunciation: TRAN-il-SIP-roe-mine SUL-fate
- Tablets 10 mg
Tranylcypromine blocks activity of enzyme MAO, thereby increasing MAO (eg, epinephrine, norepinephrine, serotonin) concentrations in CNS.
Tranylcypromine appears to be well absorbed following oral administration of 30 mg/day. T max is 3 h; however, max inhibition of MAO occurs within 5 to 7 days. There is a rapid onset of activity.
Tranylcypromine is metabolized with the release of the active metabolite. Its activation is primarily by acetylation.
The drug is excreted in 24 h.
Onset of action is from 48 h to 3 wk.
Special PopulationsSlow acetylators
Slow acetylators may yield exaggerated effects after standard dosing.
Indications and Usage
Treatment of major depressive episodes without melancholia.
Prevention of migraine; social anxiety disorders; panic disorders; bipolar depression; Alzheimer and Parkinson disease if patients are unresponsive or unable to take other agents.
Hypertension; cerebrovascular defects; cardiovascular disease; history of headache, liver disease or abnormal LFTs; presence of pheochromocytoma; in combination with other MAOIs or dibenzazepine-related entities (eg, cyclobenzaprine), antihypertensives (eg, guanethidine, methyldopa, reserpine), diuretics, antihistamines, sedatives, anesthetics (eg, general anesthesia, cocaine, local anesthesia-containing sympathomimetic vasoconstrictors), antiparkinson agents (eg, benztropine, trihexyphenidyl), tricyclic antidepressants (eg, amitriptyline), levodopa, serotoninergics (eg, fluoxetine, dexfenfluramine), tryptophan, bupropion, buspirone, sympathomimetics (eg, amphetamine), dextromethorphan, or caffeine; in combination with cheese or other foods with high tyramine content; in combination with CNS depressants (eg, alcohol, meperidine) or hypotensive agents (eg, dopamine).
Dosage and AdministrationAdults
PO Usual effective dose is 30 mg/day in divided doses. If there are no signs of improvement within 2 wk, the dosage may be increased in 10 mg/day increments at intervals of 1 to 3 wk (max, 60 mg/day).
Store at 59° to 86°F.
Drug InteractionsAmine-containing foods
Severe hypertension or hemorrhagic stroke may occur in patients taking tranylcypromine when these foods are ingested.Anesthetics (eg, cocaine, general anesthetics, local anesthetics)
Coadministration is contraindicated.Antidiabetic agents (eg, insulin, sulfonylureas)
Hypoglycemia may be potentiated and recovery delayed by tranylcypromine.Antihypertensive agents (eg, guanethidine, methyldopa, reserpine)
Hypotensive effect may be inhibited by tranylcypromine. Coadministration is contraindicated.Antihypotensive agents (eg, dopamine), antiparkinson agents
Effect may be potentiated by tranylcypromine. Coadministration is contraindicated.Atomoxetine, dextromethorphan
Risk of serious and life-threatening reactions may be increased by tranylcypromine. Coadministration is contraindicated.Bupropion
Risk of toxicity may be increased by tranylcypromine. Coadministration is contraindicated.Buspirone
Risk of increased blood pressure may be increased by tranylcypromine. Coadministration is contraindicated.Caffeine, carbamazepine, meperidine
Risk of severe side effects (eg, hyperpyrexia, muscle rigidity, seizures) may be increased by tranylcypromine. Coadministration is contraindicated.CNS stimulants (eg, amphetamines, methylphenidate), dibenzazepine-related drugs (eg, cyclobenzaprine), sympathomimetics (eg, ephedrine, phenylephrine), other MAOIs (eg, furazolidone, phenelzine), tricyclic antidepressants (eg, amitriptyline)
Hypertensive crisis may be precipitated. Coadministration is contraindicated.Dexfenfluramine, serotonin reuptake inhibitors (eg, fluoxetine, nefazodone, venlafaxine), sibutramine, tryptophan
Risk of serotonin syndrome occurrence may be increased. Coadministration is contraindicated.Disulfiram
Risk of delirium, including agitation, disorientation, and visual hallucinations, may be increased.Levodopa
Hypertensive reactions may occur. Coadministration is contraindicated.Selective 5-HT 1 receptor agonists (eg, rizatriptan, sumatriptan)
Serum levels may be elevated, increasing the risk of cardiotoxicity. Coadministration is contraindicated.
Laboratory Test Interactions
None well documented.
Agitation, anxiety, dizziness, drowsiness, headache, insomnia, manic symptoms, numbness, overstimulation, paresthesia, restlessness, tremor, weakness; akinesia, ataxia, confusion, disorientation, memory loss (postmarketing).
Alopecia, skin rash; flare-up of cystic acne, scleroderma, urticaria (postmarketing).
Blurred vision, tinnitus.
Abdominal pain, anorexia, constipation, diarrhea, dry mouth, nausea; fissures at corner of mouth (postmarketing).
Impotence, retarded ejaculation, urinary retention; urinary frequency, urinary incontinence (postmarketing).
Agranulocytosis, anemia, leukopenia, thrombocytopenia.
Muscle spasm, myoclonic jerks.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorders and other psychiatric disorders. Appropriately monitor patients of all ages who are started on antidepressant therapy and observe closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescriber.
Closely observe patient for clinical worsening, suicidality, or unusual changes in behavior during initial few months of therapy or when increasing or decreasing the dose. Closely monitor BP.
Category C .
Excreted in breast milk.
Safety and efficacy not established.
Use with caution; older patients may suffer more morbidity than younger patients.
Tranylcypromine may suppress anginal pain, which would otherwise serve as a warning of myocardial ischemia.
May aggravate coexisting symptoms, such as anxiety and agitation.
Because antidepressants may increase the likelihood of precipitation of a mixed/manic episode in patients at risk of bipolar disorder, screen patients prior to initiating treatment to determine if they are at risk for bipolar disorder.
May alter glucose control.
May lower seizure threshold.
Hypertensive crisis, which may be fatal, is the most important reaction associated with tranylcypromine administration. Discontinue treatment immediately upon occurrence of palpitation or frequent headaches.
Use with caution because of increased sensitivity to pressor amines.
Discontinue tranylcypromine at least 48 h before myelography and do not resume for at least 24 h post procedure.
Agitation, anxiety, coma, dizziness, drowsiness, hyperpyrexia, hypertension, hypotension, incoherence, insomnia, mental confusion, movement disorders, restlessness, severe headache, shock, weakness.
- Inform patient and family that it may be 3 to 4 wk before a noticeable improvement in mood is noted.
- Instruct patient to take the medication at the same time every day.
- Advise patient not to take any other medications, including OTC or prescription medications, without checking with health care provider first. This medication interacts with a large number of other medications.
- Teach patient to avoid sudden position changes to prevent orthostatic hypotension.
- Instruct patient and family on how to take BP. If the BP is markedly higher than normal, they should notify health care provider.
- Warn patient that eating foods that contain tyramine or tryptophan while taking this medication can produce hypertensive crisis, which is potentially fatal. These foods include, but are not limited to, protein foods that are aged or fermented, such as cheeses, pickled herring, liver, hard sausage, pods of broad beans, beer, red wine, yeast extract, yogurt, ginseng, soy sauce, bananas, raisins, and avocados. Arrange for a consultation with a dietitian.
- Instruct patient to ingest caffeine and chocolate only in small amounts.
- Inform patient to avoid the use of alcohol and other recreational drugs.
- Advise patient to use caution while driving or performing other tasks requiring mental alertness until effect is determined.
- Instruct patient to stop taking the medication and notify health care provider immediately if any of the following occurs: chest pain, eye pain or photophobia, nausea, rapid heart beat, severe headache, severe sweating, stiff neck, or vomiting.
- Advise patients and family to be alert for the emergence of agitation, irritability, and unusual changes in behavior as well as the emergence of suicidality, and to report such symptoms immediately to health care provides.
Copyright © 2009 Wolters Kluwer Health.
More Tranylcypromine Sulfate resources
- Tranylcypromine Sulfate Monograph (AHFS DI)
- Tranylcypromine Prescribing Information (FDA)
- Parnate Prescribing Information (FDA)
- Parnate Concise Consumer Information (Cerner Multum)
- Parnate MedFacts Consumer Leaflet (Wolters Kluwer)
- Parnate Advanced Consumer (Micromedex) - Includes Dosage Information